Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo Holdings to make an investment in Biocomposites ("the Company"), an international ...

Novo Holdings and TA Associates have agreed to make an investment into Biocomposites.

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European Commission (EC) gave its approval in early December 2024. Catalent's ...

After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic ...

The Series C – which was led by Novo Nordisk's parent company Novo Holdings – follows a $15 million second round for the South San Francisco-based company in 2017 and a $15 million Series A in ...

COPENHAGEN, Denmark, Jan. 10, 2025 /PRNewswire/ -- Novo Holdings, a leading life science investor, today announced that it has invested in a $200M Series A launch financing for Windward Bio.

The foundation is the parent company of Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, which makes the blockbuster obesity drug Wegovy and diabetes medication.

Novo Nordisk also reported the acquisition of three manufacturing sites from Novo Holdings A/S following the finalization of Novo Holdings' acquisition of Catalent, Inc. - a global contract ...

Additional investment and resources will accelerate Biocomposites' international expansion and innovation in products for use in infection management HELLERUP, Denmark, LONDON and KEELE ...